Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate ...
The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...
Vir Biotechnology, Inc. today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD). Participants receiving the combination ...
HSK39004, a novel dual‑target therapy, aims to compete in the global COPD market, highlighting innovation and international capabilitiesBEIJING, Jan. 12, ...
In May 2022, The US FDA authorized the use of RADICAVA ORS (edaravone) in an oral formulation for the treatment of ALS.
A clinical-stage biotechnology company headquartered in Palo Alto, California. The company is focused on respiratory medicine ...
Bio?Sourcing and Zerion Pharma A/S today announce that their joint project to develop an oral formulation of Trastuzumab, the pioneer monoclonal antibody used to treat breast cancer, has been awarded ...
Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in ...
The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback